Intriguingly, mice tumor vessels exhibiting high levels of α2,6-sialylation were more sensitive to anti-VEGF whereas ST6GalT-1 knockout mice lacking this modification resisted to anti-VEGF therapy [48]. The gene discussed is VEGFA; the disease is neoplasm.